Education
About Us
Working with TipRanks
Follow Us
John Scarlett Insider Profile
4 Followers
John Scarlett, COB, Pres & CEO, Director at Geron, holds 137.50K shares in Geron (Ticker: GERN), holds 0.00 shares in Chiasma (Ticker: CHMA), holds ― shares in CytomX Therapeutics (Ticker: CTMX). Most recently, John Scarlett Bought ― shares of Geron on Mar 03, 2025 for an estimated value of 22.00K.
John Scarlett has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that John Scarlett holds in companies
Most Profitable Insider Trade
The most profitable trade made by John Scarlett
John Scarlett's Trading History
Geron
Mar 03, 2025
COB, Pres & CEO, Director
Informative Buy
22.00K
$176.00K
Chiasma
Aug 05, 2021
―
Uninformative Sell
―
$0.00
CytomX Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see John Scarlett's performance on stock
You May Also Like
John Scarlett insider profile FAQ
What is the percentage of profitable transactions made by John Scarlett?
The percentage of profitable transactions made by John Scarlett is ―.
What is the average return per transaction made by John Scarlett?
The average return per transaction made by John Scarlett is ―.
What stocks does John Scarlett hold?
John Scarlett holds: GERN, CHMA, CTMX stocks.
What was John Scarlett’s latest transaction?
John Scarlett latest transaction was an Informative Buy of $22.00K.
What was John Scarlett's most profitable transaction?
John Scarlett’s most profitable transaction was an Informative Buy of GERN stock on March 3, 2025. The return on the trade was -27.40%.
What is John Scarlett's role in Geron?
John Scarlett's role in Geron is COB, Pres & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.